<img height="1" width="1" src="https://www.facebook.com/tr?id=414339248965737&amp;ev=PageView &amp;noscript=1">

Eyes on Research

Clinical Trial Support: Point of Need vs. Traditional Solutions

20/20 Onsite

GLP‑1 Clinical Trial Eye Safety: Semaglutide Eye Risks

20/20 Onsite

Imaging Isn’t Optional: What Sponsors Must Know to Safeguard Ocular Endpoints

By 20/20 Onsite

Imaging in clinical trials isn’t optional anymore; it’s foundational. In GLP-1 and neurology trials, where ocular endpoint sensitivity is everything, the quality and timing of imaging can directly... Read More

Rethinking Ophthalmic Trials: Takeaways from ARVO 2025

By 20/20 Onsite

At ARVO 2025, one truth cut through the noise: you can’t innovate at the expense of data integrity. As trials evolve to be more decentralized and patient-centric, the pressure to maintain precision,... Read More

Clinical Trial Design Strategies to Improve Patient Retention

By 20/20 Onsite

When planning a clinical trial, there's a tendency to focus on enrollment—building lists, recruiting participants, and getting sites up and running quickly. While this is important to hit deadlines... Read More

Critical Imaging Risks in GLP-1 and Neurology Studies: What You Need to Know

By 20/20 Onsite

Key Takeaways: Early engagement with imaging vendors during protocol development can prevent costly delays and amendments Preclinical imaging data should inform clinical trial design, especially for... Read More

Rethinking Decentralized Clinical Trials: Why One Size Doesn't Fit All

By 20/20 Onsite

Clinical trials are evolving rapidly. Driven by technological advancements, there is a pressing need to make studies more patient-centric. The term Decentralized Clinical Trials (DCTs) has gained... Read More

High Density, Low Availability: Rethinking Ophthalmic Trial Readiness

By 20/20 Onsite

Ophthalmic assessments are no longer mere box-checks in clinical trials. With advanced imaging and endpoints becoming the norm, sponsors must grapple with complexity and risk that extend well beyond... Read More

What Does This Mean? The Hidden Complexity of Ophthalmic Protocol Requirements

By 20/20 Onsite

For many sponsors, the full meaning of “ophthalmic assessments” might remain an afterthought until those requirements start complicating site setup, timelines, budget, or patient enrollment. Yet... Read More

Breaking Research: Semaglutide Use and Increased Risk of NAION – Implications for Clinical Trials and Patient Safety

By 20/20 Onsite

Recent research analyzing over 424,000 patients has revealed an association between semaglutide—a widely used medication for type 2 diabetes and weight management—and an increased risk of developing... Read More